Beximco Pharmaceuticals (BXP) Competitors GBX 47.11 -0.39 (-0.82%) As of 08/15/2025 11:09 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock BXP vs. LSE, WPY, AHT, LAND, TW, SIR, SAFE, CLIN, EVR, and BGSCShould you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include London Stock Exchange Group plc (LSE.L) (LSE), Worldpay (WPY), Ashtead Group (AHT), Land Securities Group (LAND), Taylor Wimpey (TW), Secure Income REIT (SIR), Safestore (SAFE), Clinigen Group (CLIN), EVRAZ (EVR), and BMO Global Smaller Companies (BGSC). These companies are all part of the "trading" industry. Beximco Pharmaceuticals vs. Its Competitors London Stock Exchange Group plc (LSE.L) Worldpay Ashtead Group Land Securities Group Taylor Wimpey Secure Income REIT Safestore Clinigen Group EVRAZ BMO Global Smaller Companies London Stock Exchange Group plc (LSE.L) (LON:LSE) and Beximco Pharmaceuticals (LON:BXP) are both large-cap trading companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Does the media prefer LSE or BXP? In the previous week, London Stock Exchange Group plc (LSE.L) had 1 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 2 mentions for London Stock Exchange Group plc (LSE.L) and 1 mentions for Beximco Pharmaceuticals. London Stock Exchange Group plc (LSE.L)'s average media sentiment score of 0.21 beat Beximco Pharmaceuticals' score of 0.20 indicating that London Stock Exchange Group plc (LSE.L) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment London Stock Exchange Group plc (LSE.L) 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beximco Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LSE or BXP a better dividend stock? London Stock Exchange Group plc (LSE.L) pays an annual dividend of GBX 73 per share. Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 6.4%. London Stock Exchange Group plc (LSE.L) pays out 64.9% of its earnings in the form of a dividend. Beximco Pharmaceuticals pays out 32.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Beximco Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio. Which has stronger earnings & valuation, LSE or BXP? Beximco Pharmaceuticals has higher revenue and earnings than London Stock Exchange Group plc (LSE.L). London Stock Exchange Group plc (LSE.L) is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLondon Stock Exchange Group plc (LSE.L)£2.41B0.00N/A£112.40N/ABeximco Pharmaceuticals£7.08T0.00£970.84B£9.325.05 Do insiders and institutionals hold more shares of LSE or BXP? 1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is LSE or BXP more profitable? Beximco Pharmaceuticals has a net margin of 13.71% compared to London Stock Exchange Group plc (LSE.L)'s net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 13.12% beat London Stock Exchange Group plc (LSE.L)'s return on equity.Company Net Margins Return on Equity Return on Assets London Stock Exchange Group plc (LSE.L)N/A N/A N/A Beximco Pharmaceuticals 13.71%13.12%6.97% SummaryBeximco Pharmaceuticals beats London Stock Exchange Group plc (LSE.L) on 7 of the 11 factors compared between the two stocks. Get Beximco Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BXP vs. The Competition Export to ExcelMetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£32.11B£2.22B£5.67B£3.09BDividend Yield8.67%2.92%3.79%5.04%P/E Ratio5.054.1930.80174.60Price / Sales0.00614.91466.77282,733.39Price / CashN/A10.3737.4027.94Price / Book0.0011.109.095.38Net Income£970.84B£20.70B£3.26B£5.89B7 Day Performance5.87%2.59%7.31%-0.13%1 Month Performance17.78%5.91%5.43%1.01%1 Year Performance39.59%3.40%30.59%64.41% Beximco Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BXPBeximco PharmaceuticalsN/AGBX 47.11-0.8%N/A+36.6%£32.11B£7.08T5.055,500Gap UpLSELondon Stock Exchange Group plc (LSE.L)N/AN/AN/AN/A£30.31B£2.41B76.694,965WPYWorldpayN/AN/AN/AN/A£29.39B£4.04B194.44190AHTAshtead Group2.2207 of 5 starsGBX 5,026+0.7%GBX 6,345+26.2%+0.4%£27.44B£13.67B17.89120News CoverageDividend CutAnalyst ForecastLANDLand Securities Group2.5703 of 5 starsGBX 586.50+1.6%GBX 671+14.4%-8.9%£4.34B£823.49M-13.60598Positive NewsTWTaylor Wimpey4.499 of 5 starsGBX 101.850.0%GBX 143.17+40.6%-38.6%£3.66B£3.45B14.861,090High Trading VolumeSIRSecure Income REITN/AN/AN/AN/A£1.49B£122.40M743.55N/ASAFESafestore4.1066 of 5 starsGBX 678+0.7%GBX 820+20.9%-23.0%£1.48B£222.85M5.59120Positive NewsCLINClinigen GroupN/AN/AN/AN/A£1.23B£565.60M64.691,000EVREVRAZ0.2889 of 5 starsGBX 81flatN/AN/A£1.18B£15.40B42.1971,591BGSCBMO Global Smaller CompaniesN/AN/AN/AN/A£769.56M£303.85M2.77N/A Related Companies and Tools Related Companies London Stock Exchange Group plc (LSE.L) Competitors Worldpay Competitors Ashtead Group Competitors Land Securities Group Competitors Taylor Wimpey Competitors Secure Income REIT Competitors Safestore Competitors Clinigen Group Competitors EVRAZ Competitors BMO Global Smaller Companies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BXP) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredJPMorgan: Gold to $4,250—Here’s the Real PlayGold Surges And Some Investors Are Getting Paid, But Most Are Not. Which One Do You Want to Be? Gold prices ar...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access